Rebecca Suk Heist, MD, MPH, discusses the treatment landscape and challenges when treating patients with second-line metastatic non-small cell lung cancer.
Back
Antibody-Drug Conjugates in NSCLC: Update on TROPION-PanTumor01 Data
Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, discuss data updates from the TROPION-PanTumor01 study that impact the use of antibody-drug conjugates as a therapy option for patients with second-line metastatic non-small cell lung cancer.
Antibody-Drug Conjugates in NSCLC: Update on TROPION-PanTumor01 Data
Episodes
All
All
Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, define Trop-2 in relation to treatments for non-small cell lung cancer and discuss what antibody-drug conjugates are being developed to target it.
Drs Heist and Peters examine data from the lung cohort of TROPION-PanTumor01 study that focused on dopotomab deruxtecan (Dato-DXd) as an antibody-drug conjugate therapy option.
Two experts discuss additional studies with antibody-drug conjugates targeting non-small cell lung cancer and the impact of their data on therapeutic options for the disease.
Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, reflect on treatments being developed in the non-small cell lung cancer space that they are excited for and provide some key takeaways and advice for colleagues.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5